Leveraging Proteomics to Identify Treatment-Responsive Biomarkers in a Rare Genetic Fibrotic Liver Disease (AATD-LD)

• Explore how high-throughput Olink proteomics and single-nucleus RNA sequencing (Snucseq) can be combined to map dynamic changes in protein expression across liver cell types in response to therapy
• Highlight treatment responsive individual proteins and pathways involved in cell stress, inflammation, and ECM remodeling
• Discuss the translational relevance of circulating biomarkers as indicators of therapeutic response in hepatocyte damage and subsequent information and fibrosis in AATD-LD with implications for broader fibrotic liver disease contexts

Speakers:

Jen-Chieh Chuang

Global Program Lead & Translational Med & Biomarker Lead, Liver Diseases

Takeda Pharmaceutical